| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Commercial Officer | EVP, COO, Head of Commercial | EVP, COO, Head of Commercial
2 companies
Brendan Teehan is Chief Commercial Officer at PCRX, with reported holdings spanning 2 companies. Brendan Teehan's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $5.0M at current prices.
Our model assigns Brendan Teehan a middling insider score of 62/100, based on 16 past trades. Over a 12-month horizon, 68.8% of those trades were profitable, with an average 12-month return of +1.4%.
Brendan Teehan's largest disclosed position is in PCRX as Chief Commercial Officer, worth about $3.7M.
Brendan Teehan has 23 Form 4 filings on record from November 2021 to February 2026, across 2 companies: Chief Commercial Officer at Pacira BioSciences (PCRX), 2025–2026; EVP, COO, Head of Commercial at Acadia Pharmaceuticals (ACAD), 2021–2024.
The 49 reported transactions were 17 option exercises, 16 open-market sales, 9 option or other derivative awards and 6 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 16 sales worth about $1.1M.
The largest open-market sale was 14,869 shares of ACAD at an average $22.50 on May 17, 2023, about $335K. Twelve months later ACAD was down 35%.
None of the 11 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 19, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 10,329 | $16.81 | $173,630.49 | -14.3% | +21.8% | +42.5% | |
| Aug 19, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sell | 9,534 | $15.28 | $145,679.52 | -15.4% | +8.1% | +58.4% | |
| May 2, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 3,477 | $16.94 | $58,900.38 | -7.6% | +11.4% | -12.7% | |
| Apr 8, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 2,568 | $17.87 | $45,890.16 | -6.2% | -8.3% | -20.8% | |
| Mar 27, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sell | 5,140 | $17.90 | $92,006.00 | -12.4% | -14.3% | -5.5% | |
| Feb 26, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 624 | $24.67 | $15,394.08 | -1.9% | -41.7% | -26.6% | |
| Jan 8, 2024 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 731 | $29.96 | $21,900.76 | -2.3% | -40.9% | -42.3% | |
| Nov 20, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 4,960 | $22.64 | $112,294.40 | -14.0% | +8.4% | -29.3% | |
| May 17, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 14,869 | $22.50 | $334,552.50 | -37.9% | +26.6% | -34.5% | |
| May 1, 2023 | ACAD Acadia Pharmaceuticals Inc | EVP, COO, Head of Commercial | Sale+OE | 548 | $21.18 | $11,606.64 | -5.5% | +34.4% | -23.2% |